Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $126,719.91 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the transaction, the director now owns 447,857 shares in the company, valued at $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $16.24 on Friday. The company has a market capitalization of $821.79 million, a price-to-earnings ratio of -10.09 and a beta of 1.04. Tyra Biosciences, Inc. has a fifty-two week low of $12.34 and a fifty-two week high of $29.60. The firm has a 50-day simple moving average of $15.38 and a 200-day simple moving average of $19.17.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. HighVista Strategies LLC purchased a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $257,000. Franklin Resources Inc. purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $278,000. Valence8 US LP purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $310,000. SG Americas Securities LLC purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $311,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $333,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TYRA. UBS Group began coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, January 13th. Wedbush restated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.